Generic version of Risperdal gains FDA OK
Teva won approval for a generic version of the popular anti-psychotic drug
 | Slide show |
 | Biggest losers: Before and after See the amazing transformations and pounds shed by the season five contestants. more photos |
updated 7:25 p.m. ET June 30, 2008
NEW YORK - Johnson & Johnson's blockbuster anti-psychotic drug Risperdal will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version.
Israel-based Teva received Food and Drug Administration approval for a generic version of the blockbuster drug, used to treat schizophrenia and bipolar disorder, among other conditions. New Brunswick, N.J.-based Johnson & Johnson's Janssen unit had expected Risperdal's patent expiration this month, followed by tough generic competition over the key revenue driver.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Discuss Story On Newsvine
- Rate Story:
View popularLowHigh - Instant Message
MORE FROM HEALTH |
 Health Section Front |
| Add Health headlines to your news reader: |